Mediator Antagonists - PowerPoint PPT Presentation

About This Presentation
Title:

Mediator Antagonists

Description:

Mediator Antagonists Chapter 12 – PowerPoint PPT presentation

Number of Views:115
Avg rating:3.0/5.0
Slides: 22
Provided by: Lean95
Category:

less

Transcript and Presenter's Notes

Title: Mediator Antagonists


1
Mediator Antagonists
  • Chapter 12

2
Mechanisms of inflammation in asthma
  • Types of asthma
  • Extrinsic dependent on allergies
  • Intrinsic shows no sensitization to allergens
  • With both forms airway inflammation is evident
    causing bronchoconstriction, airway swelling,
    mucus secretion and obstruction

3
Allergic response
  • Primarily involves mast cells and immunoglobin E
  • Lymphocytes (T cells) activated by an antigen
    result in the production of IgE
  • IgE binds to mast cells
  • Releases mediators of inflammation such as
    prostaglandins, leukotrienes, histamine, platelet
    aggregating factor, and cytokines

4
Allergic response
  • Mediators from mast cell cause vascular leakage,
    bronchoconstriction, mucus secretion, and mucosal
    swelling
  • Once initiated the inflammatory response causes
    the release of eosinophils, neutrophils, and
    lymphocytes which increase the severity of the
    inflammation

5
Disodium cromoglycate/Cromolyn sodium
  • Comes from the seeds of a plant Ammi visagna
  • Extract of khellin taken from here-originally
    used to treat colic
  • Prophylactic agent to prevent asthmatic reactions
  • Not related to any other drug category such as
    beta agonists, xanthines, or glucocorticoids

6
Indications for use
  • Prophylactic management of asthma
  • Prevention of exercise induced asthma
  • For allergic rhinitis
  • Extrinsic asthma

7
Mode of action
  • Prevents mast cell degranulation
  • Blocks release of chemical mediators
  • Must be used as a pretreatment
  • May work by preventing calcium from allowing the
    contraction of the filaments on the mast cell
    which release the mediators
  • Does not work as an antagonist on the mediators
    themselves
  • Does not affect alpha or beta receptors

8
Mode of action cont.
  • Does not prevent antibody formation, the
    attachment of IgE, and the combination of
    antibody-antigen reactions-only prevents the
    release of the mediators

9
Dosage and administration
  • Spinhaler (dry powder inhaler)-can be irritating
    and cause coughing or bronchoconstriction. May
    need beta 2 agonist prior to or after tx.
  • Ampule for nebulization (20 mg/2ml). Brand names
    Aarane or Intal
  • MDI
  • Nasal solution(Nasalcrom)

10
Side Effects
  • Safe drug
  • Dry powder causes throat irritation, hoarseness,
    dry mouth
  • Nebulizers associated with cough, wheezing,
    sneezing

11
Clinical Applications
  • Drug is only prophylactic and should not be used
    during acute bronchospasm. No bronchodilating
    action.
  • No affect on the adrenal system and cant be used
    as replacement for corticosteroids
  • May take 2 to 4 weeks for improvement in
    patients symptoms

12
Nedocromil sodium (Tilade)
  • Cromolyn sodium type drug
  • Prophylactic therapy for asthma management
  • Inhibits mast cell mediator release
  • Can inhibit eosinophil activity

13
Leukotrienes
  • Production from leukocytes.
  • Release of leukotrienes during inflammatory
    reaction causes narrowed airways, excessive mucus
    production, airway inflammation

14
Role of leukotrienes in asthma
  • Leukotrienes originally called SRSA
  • Released by inflammatory cells
  • Directly contract airway smooth muscle
  • 1000 x more potent than histamine in causing
    bronchial contraction and the contraction lasts
    longer
  • Also stimulate hypersecretion of mucus

15
Leukotrienes
  • Also stimulate vascular permeability which causes
    airway swelling

16
Antileukotriene therapy
  • Inhibit the production and block the action of
    leukotrienes
  • Two main classes leukotriene synthesis
    inhibitors and leukotriene receptor antagonists

17
Pharmacologic agents
  • Montelukast (singulair)
  • Leukotriene receptor antagonist
  • Blocks leukotrienes at receptor site
  • Improves airway obstruction, may keep episodes
    from worsening in chronic asthma

18
Pharmacologic agents
  • Zafirlukast (Accolate)
  • Receptor antagonist used in the tx of chronic
    asthma
  • Inhibits bronchoconstriction.

19
Pharmacologic agents
  • Zileuton (Zyflo)Inhibits formation of
    leukotrienes
  • Inhibits bronchoconstriction caused by various
    allergens

20
Side effects
  • Accolate(Zafirlukast)-headache, nausea, diarrhea,
    abdominal pain, infection
  • Zileuton(Zyflo)-headache, abdominal pain, loss of
    strength, stomach upset
  • Montelukast(Singulair)- does not have these side
    effects

21
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com